Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2013

View Archived Issues

Kinexus updates on PhosphoNET KnowledgeBase

New immunohistochemistry kit for diagnosis and prognosis of invasive tumors

New means of converting stem cells to naive state discovered at Minerva Biotechnologies

Stanford University presents new PKC-delta inhibitors

Scientists at the University of Utah present novel LSD1 inhibitors for cancer

Diaxonhit presents new DYRK1A/1B inhibitors

Vasomera demonstrates improvement in left ventricular function in vivo

Preclinical results for intranasal gemcitabine

Danegaptide hydrochloride shown to reduce infarct size in vivo

Tenecteplase significantly affects primary outcome measure in PEITHO trial

Tragara Pharmaceuticals presents pharmacokinetic data for TG-02 citrate

Boehringer Ingelheim presents new agents for viral infections

Merck KGaA divulges new FAK inhibitors

Takeda Pharmaceutical synthesizes new DAAO inhibitors

Gedeon Richter and Orion Corporation to collaborate on cognitive disorders

Biogen Idec submits BLA for factor VIII therapy

Chimerix's CMX-001 obtains FDA fast track status for cytomegalovirus infections

Vifor Pharma reports new regulatory submission for PA-21 in Switzerland

Shire acquires biotechnology company

Lithera begins phase IIb trial of LIPO-202 for the reduction of subcutaneous fat

Detailed results from CHAMPION PHOENIX cangrelor trial presented

Presidio and Boehringer Ingelheim to collaborate on study of combination treatment for HCV infection

Armetheon to develop tecarfarin as alternative to warfarin

Qurient gains exclusive worldwide rights to new kinase inhibitor for metastatic cancer

FDA approves IND for phase I/II trial of ACT's hESC-derived cells to treat severe myopia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...